Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Amer Sports Inc (AS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Amer Sports Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Amer Sports Inc trades at $33.44 (market cap $19.80B). The key difference: Amer Sports Inc is far larger — about 4.4× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Amer Sports Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | AS | |
|---|---|---|
Market Cap | $4.49B | $19.80B |
Sector | Health | Technology |
52-Week High | $28.06 | $41.96 |
52-Week Low | $20.06 | $29.54 |
Enterprise Value | $3.69B | $20.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Amer Sports (AS) trades at $34.84, down 0.6% on the day, with a neutral technical outlook. The company reported strong Q1 2026 results, beating EPS estimates with $0.38 versus $0.31 expected, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion. Analyst sentiment is overwhelmingly positive, with 12 of 14 analysts rating it a Buy and a consensus price target of $56.00, implying significant upside. Operating cash flow remains robust at $729.80 million for 2025.
The outlook is favorable given consistent earnings beats and raised guidance, but risks include high valuation multiples (P/E of 43.54) and dependence on the Arc'teryx brand's sustained momentum. The stock presents a growth opportunity if execution continues, though premium valuation requires careful monitoring of margin trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →
